Patient Summary - Prashanth H K, 34M, 73 kg

Part 1: Pathophysiology and Etiology of Hypercholesterolemia in Hypothyroidism/Hashimoto's

Mechanism 1 - LDL Receptor Downregulation (Primary Mechanism)

• Fewer LDL receptors on hepatocytes → less LDL cleared from blood → LDL-C accumulates
• This is why hypothyroidism is the single most important medical condition causing elevated LDL-C (Harrison's Principles, 22E)
• Thyroid hormone replacement normally reverses this - but in this patient, TSH is controlled yet LDL remains elevated, suggesting a co-existing primary lipid disorder or residual T3-receptor tissue resistance

Mechanism 2 - Reduced LPL Activity

• Reduced LPL activity → impaired VLDL and TG clearance
• Accumulation of VLDL remnants and intermediate density lipoproteins (IDL)
• Explains the elevated TG (242 mg/dL) and VLDL (48 mg/dL) in this patient

Mechanism 3 - Reduced Affinity of Remnant Particles for LDL Receptor

Mechanism 4 - Decreased Cholesterol-to-Bile Acid Conversion

• Less cholesterol converted to bile acids
• Hepatocellular cholesterol rises → downregulates LDL receptor further
• A self-amplifying cycle

Mechanism 5 - Cholesterol Ester Transfer Protein (CETP) Dysfunction

• Dysfunctional HDL that cannot be recharged with cholesterol esters efficiently
• Very low HDL (33 mg/dL in this patient)

Mechanism 6 - Insulin Resistance & Increased Obesity

• Increases free fatty acid delivery to the liver
• Stimulates hepatic VLDL overproduction
• Further reduces HDL

Mechanism 7 - Residual Tissue Hypothyroidism Despite Normal TSH

Part 2: Why This Patient Still Has Dyslipidemia Despite Normal TSH

1. Residual low-normal T3 (0.75 ng/mL) - inadequate for full LDL receptor upregulation
2. T4 monotherapy effect - Levothyroxine (T4 only) relies on peripheral deiodinase activity for T3 conversion; some Hashimoto's patients have reduced deiodinase function
3. Co-existing primary lipid disorder - the severely low HDL (33 mg/dL) with very high TG (242 mg/dL) and elevated VLDL suggests a possible metabolic syndrome or co-existing familial combined hyperlipidemia (FCHL)
4. Vitamin D insufficiency - Vitamin D at 30 ng/mL (borderline) has been associated with dyslipidemia; deficiency correlates with elevated LDL and TG
5. Diet and lifestyle - the magnitude of this dyslipidemia (all fractions abnormal) strongly suggests dietary contribution

Part 3: Cardiovascular Risk Assessment

• LDL 144 mg/dL
• TG 242 mg/dL
• HDL 33 mg/dL (severely low)
• TC/HDL ratio 7 (very high; reference 3.3-4.4)
• LDL/HDL ratio 4.4 (high)
• Hashimoto's hypothyroidism (chronic inflammatory state)

Part 4: Detailed Management Plan

Step 1 - Optimize Levothyroxine Therapy (PRIMARY STEP)

• Current TSH: 0.68 - within target range, but check FT4 and FT3 (not done here - total T3/T4 only)
• Consider requesting Free T3 (FT3) and Free T4 (FT4) - more clinically meaningful than total T3/T4 since total values are affected by binding proteins
• If FT3 is low-normal, consider whether the dose of levothyroxine needs optimization or whether the patient is a candidate for T4+T3 combination therapy (discussed in Hashimoto's management context)
• Target TSH for Hashimoto's on levothyroxine: 0.5-2.5 µIU/mL - this patient is already in range
• Per Harrison's: "Thyroid replacement therapy usually reduces LDL-C levels; if not, the patient probably has a primary lipoprotein disorder and may require lipid-lowering drug therapy." Since TSH is now controlled yet lipids remain deranged, additional lipid therapy is indicated.

Step 2 - Therapeutic Lifestyle Changes (TLC) - Mandatory First 3 Months

• Saturated fat: Reduce to <7% of total calories (saturated/trans fats directly downregulate LDL receptors, compounding the hypothyroid effect)
• Dietary cholesterol: <200 mg/day
• Soluble fiber: 10-25 g/day (oats, psyllium, legumes) - reduces LDL by 3-5%
• Plant sterols/stanols: 2 g/day (fortified foods or supplements) - reduces LDL by 6-15%
• Omega-3 fatty acids: 2-4 g/day (EPA + DHA) - specifically targets hypertriglyceridemia; TG of 242 will respond well
• Eliminate refined carbohydrates and sugar - major driver of VLDL/TG elevation
• Mediterranean diet pattern - best evidence for TG reduction and HDL improvement

• Aerobic exercise 150 min/week moderate intensity - raises HDL (currently severely low at 33)
• Resistance training 2x/week
• Weight management to target body weight

Step 3 - Pharmacological Therapy

Decision Framework:

• LDL 144 (target <100, ideally <70 for high-risk)
• TG 242 (target <150)
• HDL 33 (severely low - target >50)
• No diabetes, creatinine normal (1.1), liver enzymes normal
• Age 34 - young, so long-term treatment planning matters

Drug 1 - Statin (for LDL)

• Hypothyroidism slows hepatic metabolism of statins (CYP3A4 reduced)
• Reduced renal clearance
• Myocyte metabolic vulnerability

• Rosuvastatin 10 mg/day (preferred) - hydrophilic, less muscle penetration, less myopathy risk
  • Expected LDL reduction: 46-52%
  • Expected TG reduction: 20-28%
  • Expected HDL increase: 4-8%
  • Does NOT require CYP3A4 for metabolism (unlike atorvastatin/simvastatin) - safer in hypothyroidism
  • Less drug-drug interaction with levothyroxine
• Alternative: Atorvastatin 10-20 mg (moderate intensity) if rosuvastatin not tolerated
• Avoid: Simvastatin (high myopathy risk in hypothyroidism), Lovastatin

• CK level (check before and at 6 weeks)
• Fasting lipid profile (done)
• LFT (done - normal)
• Creatinine (done - 1.1, normal)

Drug 2 - For Triglycerides (TG 242 mg/dL)

• Fenofibrate 145 mg/day (preferred over gemfibrozil with statins)
  • Expected TG reduction: 35-50%
  • Raises HDL: 6-18% (very beneficial here given HDL of 33)
  • Mild LDL reduction: 10-15%
  • CAUTION: Use fenofibrate (not gemfibrozil) with statin - safer combination; space 12 hours apart
  • Monitor: creatinine, CK, LFT at 8 weeks
  • Safe with creatinine 1.1 (dose reduce if creatinine >2)

• Omega-3 fatty acids (prescription-grade): Icosapent ethyl (EPA) 4 g/day
  • Reduces TG by 20-30%
  • Cardiovascular benefit shown in REDUCE-IT trial (high-TG, high-CV-risk patients)
  • No myopathy risk - can be used safely with statins in hypothyroidism
  • Preferred when there is concern about the statin + fibrate combination

Drug 3 - For Low HDL (33 mg/dL)

• Fenofibrate (as above) - best pharmacological agent for raising HDL
• Exercise - the most effective non-pharmacological HDL raiser
• Niacin is no longer recommended as add-on therapy (AIM-HIGH trial negative)
• Eliminate smoking if present

Summary Pharmacological Plan:

Step 4 - Monitoring Plan

Step 5 - Anti-TPO Antibodies

Part 5: Special Considerations - Hashimoto's and Lipids

1. Autoimmune-mediated endothelial dysfunction - anti-TPO antibodies and anti-thyroglobulin may directly affect vascular endothelium
2. Increased Lipoprotein(a) [Lp(a)] - Consider checking Lp(a) in this patient; autoimmune thyroid disease is associated with elevated Lp(a), which is not reduced by statins and increases residual ASCVD risk
3. CRP elevation - Check hs-CRP; chronic inflammation from Hashimoto's can elevate CRP, which further stratifies cardiovascular risk
4. NAFLD risk - Hypothyroidism is an independent risk factor for non-alcoholic fatty liver disease (NAFLD), which can independently worsen dyslipidemia. Liver enzymes are currently normal - good sign.

Summary of Action Points for Prashanth H K

1. Order FT3, FT4 - to assess true free hormone levels (current labs only show total T3/T4)
2. Order: fasting glucose, HbA1c, hs-CRP, Lp(a), anti-TPO (if not done)
3. Continue Levothyroxine 100 mcg - TSH well controlled. May titrate based on FT3 result.
4. Start Rosuvastatin 10 mg/day - for LDL and overall CV risk reduction
5. Add Omega-3 fatty acids (EPA 4 g/day) or Fenofibrate 145 mg/day - for TG 242 and low HDL
6. Start Vitamin D3 2000-4000 IU/day with calcium if dietary intake inadequate
7. Aggressive lifestyle modification - low saturated fat diet, Mediterranean pattern, aerobic exercise, omega-3 rich diet
8. Recheck: Lipid profile + CK + LFT at 8-12 weeks
9. Annual ASCVD risk assessment using pooled cohort equations

• Harrison's Principles of Internal Medicine, 22E (2025) - Chapter 419, Secondary Hypercholesterolemia
• Fitzpatrick's Dermatology, 9th Ed - Thyroid dysfunction and dyslipidemia mechanisms
• Goodman & Gilman's Pharmacological Basis of Therapeutics - Statin myopathy in hypothyroidism
• Nishat S et al. "Effect of Levothyroxine Therapy on the Lipid Profile of Patients With Hypothyroidism: A Systematic Review." Cureus, 2024. PMID 39184762
• Braunwald's Heart Disease, 2-Vol Set - Cardiovascular risk in thyroid disorders

Updated Clinical Picture - Key New Information

RED FLAG - Prior Statin Toxicity History

• Untreated/undertreated hypothyroidism (was on 125 mcg but TSH was presumably not well-controlled at that time, given dose was later adjusted) + statin

Is Statin Use Safe NOW?

Why the Risk is NOW Lower (But Not Zero):

Conditions That MUST Be Met Before Restarting a Statin:

1. Check baseline CK now - if elevated (>3x ULN = >570 U/L) without statin, do NOT start statin until normalized
2. Confirm euthyroid state - TSH 0.68 is well-controlled - this condition is MET
3. Identify which statin caused the prior event - to avoid the same molecule
4. Ensure creatinine is stable - currently 1.1, acceptable

Statin Selection - Safest Options in This Patient

The Critical Pharmacology Distinction:

Revised Complete Management Plan

Phase 1 - Before Starting Any Statin (Do This First)

Phase 2 - Levothyroxine Dose Assessment

• Do NOT reduce further - TSH is already at lower-normal
• If FT3 comes back low-normal (which may explain persistent dyslipidemia despite normal TSH), discuss with endocrinologist whether a low-dose T3 supplementation (liothyronine 5-10 mcg) or switch to combination T4/T3 is warranted - some Hashimoto's patients have suboptimal peripheral T4→T3 conversion
• Check dose timing: Levothyroxine must be taken on empty stomach, 30-60 min before food. Calcium, iron supplements, and PPIs must be separated by 4 hours (these reduce absorption and could mean 100 mcg is functionally less than prescribed)
• Steady state after any dose change: recheck TSH in 6 weeks

Phase 3 - Pharmacological Lipid Management

Drug 1 - Statin (with extreme caution)

• Starting dose 5 mg (not 10-20 mg) given prior myopathy history
• Titrate to 10 mg only after 8-12 weeks with confirmed normal CK
• Expected LDL reduction at 5 mg: ~38-42%
  • LDL 144 → expected ~85-90 mg/dL (near target of <100)
• Expected TG reduction: ~15-20%
• Monitor CK at 2 weeks, 6 weeks, 3 months
• Stop immediately if CK >10x ULN OR any muscle pain - do not wait

Drug 2 - Ezetimibe (complementary to statin, no myopathy risk)

• Mechanism: blocks intestinal cholesterol absorption (NPC1L1 transporter) - entirely different from statins
• No CYP3A4 involvement, no muscle penetration, no myopathy risk of its own
• LDL reduction: ~18% additional on top of statin
• Combined Rosuvastatin 5 mg + Ezetimibe 10 mg = ~55-60% LDL reduction
  • LDL 144 → expected ~58-64 mg/dL (excellent, exceeds target)
• Note: Ezetimibe with statin can rarely contribute to myopathy (synergistic), but this is uncommon and the combination is far safer than high-dose statin monotherapy
• Per Katzung: "Ezetimibe is the drug of choice for patients who cannot tolerate statins or in whom statin dose escalation is limited by side effects"

Drug 3 - Saroglitazar (already prescribed - CONTINUE + OPTIMIZE)

Drug 4 - Omega-3 Fatty Acids (adjunctive)

• Add Omega-3 (EPA/DHA) 2-4 g/day - safe, no drug interactions, directly lowers TG
• Icosapent ethyl (EPA-only) has cardiovascular outcome data (REDUCE-IT trial)

Drugs to AVOID in This Patient

Phase 4 - Pre-Diabetes Management (FBS 102, HbA1c 5.4)

• Saroglitazar (PPARγ) is already helping insulin sensitivity - continue
• Metformin is NOT yet indicated (HbA1c <5.7% = normal, FBS 102 is borderline; full pre-diabetes = HbA1c 5.7-6.4%)
• Lifestyle: 5-7% weight loss prevents conversion to T2DM by ~58% (DPP trial)
• Recheck HbA1c + FBS in 6 months

Phase 5 - NAFLD Management

• Saroglitazar: Continue 4 mg/day (established NAFLD therapy in India)
• Liver enzymes currently normal (ALT 26, AST 24) - good sign
• Avoid: alcohol, hepatotoxic drugs, high fructose intake
• Rosuvastatin is safe and can be used in NAFLD - it actually reduces hepatic steatosis in some studies
• Vitamin E (800 IU/day) is an option for non-diabetic NAFLD but discuss risks
• Monitor LFT every 6 months on saroglitazar + statin

Summary Decision Chart

Prior statin myopathy + hypothyroidism + NAFLD + pre-diabetes
                         ↓
Step 1: Baseline CK + FT3/FT4 (before ANY statin)
                         ↓
CK normal? → START Rosuvastatin 5 mg (NOT atorvastatin/simvastatin)
                         ↓
Add Ezetimibe 10 mg immediately (LDL-lowering without myopathy risk)
                         ↓
Continue Saroglitazar 4 mg (TG + VLDL + NAFLD + insulin resistance)
                         ↓
Continue Levothyroxine 100 mcg (TSH well-controlled at 0.68)
                         ↓
Check CK at 2 weeks, 6 weeks - any muscle pain = STOP statin
                         ↓
Recheck full lipid panel + CK + LFT at 8-12 weeks
                         ↓
Titrate Rosuvastatin to 10 mg only if CK normal and well-tolerated

Monitoring Schedule

Key Takeaways for This Case

1. Prior CPK rise + myalgia + AKI = statin-induced myotoxicity in undertreated hypothyroidism - not a coincidence, well-documented mechanism
2. Now euthyroid (TSH 0.68) = lower risk, but prior susceptibility means lifelong caution
3. Rosuvastatin 5 mg + Ezetimibe 10 mg = safer, more effective combination than any high-dose statin alone - same or better LDL lowering with far less myopathy risk
4. Saroglitazar is already addressing TG/VLDL/NAFLD/insulin resistance - a strategically excellent drug for this metabolic phenotype
5. Check CK before starting - if still elevated at baseline (residual myopathy), investigate further before any statin
6. Never use gemfibrozil with statin in this patient - use fenofibrate only if fibrate needed

This Changes the Risk Assessment Completely

The Single Most Important Insight

• He does NOT have a history of statin-induced myopathy - that risk category is cleared
• His muscles were vulnerable due to hypothyroid metabolic damage, not drug toxicity
• Now that he is euthyroid, that vulnerability is resolved

Can Statins Be Started Now? - Direct Answer

YES - Statins can and should be started now, with appropriate precautions.

Pre-Statin Checklist (3 Steps)

Step 1 - Check CPK NOW (Before Day 1 of Statin)

Step 2 - Confirm Euthyroid State

Step 3 - Confirm Creatinine Stable

Residual Risks That Do Still Exist (Lower, Not Zero)

Statin Recommendation - Final Answer

Rosuvastatin 5-10 mg once daily

1. Not metabolized by CYP3A4 - avoids the metabolic bottleneck that hypothyroidism creates in hepatic drug clearance. Even though thyroid is now controlled, baseline hepatic function in NAFLD patients can be subtly reduced
2. Hydrophilic - does not penetrate skeletal muscle cells as easily as lipophilic statins (atorvastatin, simvastatin) → lower intrinsic myopathy risk
3. Most potent per mg - achieves excellent LDL reduction at low doses, so you don't need high doses
4. Safe in mild renal impairment - relevant given his creatinine history

Monitoring Protocol After Starting Statin

• If any muscle pain, weakness, dark urine (myoglobinuria), or flu-like symptoms develop → stop statin immediately and call doctor - do not wait for next appointment
• Take Rosuvastatin at any fixed time daily (unlike atorvastatin, timing not critical)
• Keep 2-4 hours gap between Levothyroxine and any other medications
• Vitamin D supplementation will reduce residual muscle vulnerability

Summary in One Paragraph

If Baseline CK is Normal - Green Light to Start

What "Normal CK" Means Clinically in This Patient

• No residual hypothyroid myopathy - muscles have fully recovered from the TSH-110 episode
• No ongoing autoimmune muscle inflammation despite Anti-TPO positivity
• No subclinical rhabdomyolysis
• Hepatic and muscle metabolism are functioning normally
• Statin catabolism pathways are intact - the drug will be cleared normally

Exact Prescription to Start

Drug 1 - Rosuvastatin 5 mg

• Dose: 5 mg once daily, any fixed time
• Why 5 mg and not 10 mg to start:
  • This patient has NAFLD (even with normal LFTs, hepatic drug processing may be mildly altered)
  • Saroglitazar is on board (PPARα/γ agonist with fibrate-like properties - adds mild background muscle metabolic load)
  • Conservative start = same efficacy trajectory with lower risk
  • At 5 mg Rosuvastatin: LDL reduction ~38-42%
  • LDL 144 × 0.60 = ~86 mg/dL - already near target of <100
• Escalate to 10 mg at week 12 if:
  • CK remains normal
  • No muscle symptoms
  • LDL not at target yet

Drug 2 - Ezetimibe 10 mg

• Start simultaneously with Rosuvastatin (not after)
• Entirely different mechanism - blocks intestinal cholesterol absorption
• No CYP3A4 involvement, no muscle penetration
• Adds 18-20% additional LDL reduction on top of statin
• Combined effect of Rosuvastatin 5 mg + Ezetimibe 10 mg:

Drug 3 - Saroglitazar 4 mg (already prescribed - CONTINUE)

• TG 242 → expected 30-40% reduction = ~145-170 mg/dL
• VLDL 48 → will normalize
• NAFLD - liver steatosis reduction
• Pre-diabetes / insulin resistance

The ONE Monitoring Rule That Cannot Be Skipped

"If you develop any muscle aching, weakness, heaviness in the legs, or notice dark/cola-colored urine at any point after starting this tablet - stop it that day and call us. Do not wait for the next appointment."

Risk Level in Plain Numbers

Complete Prescription Summary

Rx 1: Tab Rosuvastatin 5 mg — once daily at night
       (Review at 12 weeks; escalate to 10 mg if CK normal and LDL not at target)

Rx 2: Tab Ezetimibe 10 mg — once daily (any time, can combine with rosuvastatin)

Rx 3: Tab Saroglitazar 4 mg — once daily (already on; continue)

Rx 4: Tab Levothyroxine 100 mcg — empty stomach, 30-60 min before breakfast
       (continue; TSH well-controlled at 0.68)

Rx 5: Vitamin D3 2000 IU — once daily with food
       (Borderline Vit D 30 ng/mL; muscle protective; recheck at 3 months)

Lifestyle: Mediterranean diet, aerobic exercise 150 min/week,
           eliminate refined carbs/sugar (TG 242, pre-diabetes)

What Stopping Saroglitazar Means for This Patient

The Rebound Risk

• The hypertriglyceridemia that was partially controlled may drift back up or worsen
• TG is already at 242 without statin coverage
• NAFLD hepatic steatosis may progress without PPARα/γ stimulation
• Insulin resistance (pre-diabetes FBS 102) may worsen

Revised Complete Prescription (Without Saroglitazar)

The New Strategy: 3-Drug Combination Targeting All Lipid Fractions

Drug 1 - Rosuvastatin 5-10 mg (for LDL + partial TG)

• Rosuvastatin at 10 mg reduces TG by ~20-28% - more TG reduction than most other statins
• This is one reason rosuvastatin is preferred here over atorvastatin - better TG profile

Drug 2 - Ezetimibe 10 mg (for LDL, no TG effect)

Drug 3 - Fenofibrate 145 mg once daily (replaces saroglitazar's PPARα function)

• PPARα agonist - directly replaces the PPARα mechanism of saroglitazar
• Reduces TG by 35-50% - the most potent TG-lowering drug class
• Raises HDL by 6-18% - important as HDL is critically low at 33 mg/dL
• Mild LDL reduction: 10-15%
• Has hepatoprotective effects in NAFLD - partially addresses what saroglitazar was doing for the liver
• Safe with Rosuvastatin (fenofibrate does NOT inhibit glucuronidation unlike gemfibrozil - much safer combination)

• Fenofibrate + Rosuvastatin = Safe ✓
• Gemfibrozil + any statin = Dangerous (doubles statin plasma levels) - never use this combination

Drug 4 - Omega-3 Fatty Acids 2 g/day (adjunctive, optional)

• Add Omega-3 EPA/DHA 2 g/day with food
• No CYP3A4 interaction, no myopathy risk, safe with all three drugs
• Additional TG reduction 15-20%
• Also has a mild NAFLD benefit (reduces hepatic steatosis)

NAFLD - What Replaces Saroglitazar?

Final Updated Complete Prescription

Rx 1: Tab Rosuvastatin 5 mg — once daily at night
       ↑ to 10 mg at week 12 if CK normal and LDL not at target

Rx 2: Tab Ezetimibe 10 mg — once daily (with or without food)

Rx 3: Tab Fenofibrate 145 mg — once daily with food
       (replaces PPARα function of saroglitazar for TG + HDL + NAFLD)
       Space 2 hours from Rosuvastatin if possible; monitor CK + LFT at 8 weeks

Rx 4: Vitamin E (d-alpha tocopherol) 400 IU — once daily with food
       (NAFLD hepatoprotection; replaces saroglitazar's hepatic benefit)

Rx 5: Tab Levothyroxine 100 mcg — empty stomach, 30-60 min before breakfast

Rx 6: Vitamin D3 2000 IU — once daily with food (borderline 30 ng/mL)

Omega-3 EPA/DHA 2 g/day — add at 12-week review IF TG >150 persists

Monitoring After This Regimen

One Important Flag on Pre-Diabetes

• Monitor FBS and HbA1c every 6 months
• Intensify lifestyle: aerobic exercise is the single best PPARγ-equivalent for insulin sensitization
• If FBS rises above 110 or HbA1c reaches 5.7+ on repeat testing, consider Metformin 500 mg for diabetes prevention

Summary

• Fenofibrate 145 mg → takes over PPARα/TG/HDL/NAFLD role
• Rosuvastatin 5-10 mg + Ezetimibe 10 mg → handles LDL comprehensively
• Vitamin E → fills the NAFLD hepatoprotection gap
• Lifestyle intensification → compensates for lost PPARγ insulin sensitivity

Renal Effects of Each Prescribed Drug - Prashanth H K (Creatinine 1.1, eGFR ~78 mL/min)

1. Rosuvastatin - Mildly Renoprotective ✅

Evidence:

• Multiple meta-analyses show statins improve eGFR and reduce proteinuria in CKD patients
• KDIGO 2024 guidelines recommend statin or statin/ezetimibe for all CKD patients with eGFR <60 - grade 1A recommendation (strongest possible)
• Meta-analysis of 24,278 patients across 16 trials: both atorvastatin and rosuvastatin improved eGFR
• Mechanism: statins reduce glomerular inflammation, mesangial cell proliferation, and oxidative stress in the kidney

How it helps this patient:

• His creatinine rose to 1.8 during the hypothyroid episode - meaning he has had AKI and partial recovery
• The residual creatinine at 1.1 with eGFR ~78 places him in CKD G2 (mildly reduced)
• Statin therapy at this stage is the standard of care to protect remaining nephron mass
• Reduces cardiovascular events in CKD (SHARP trial: statin + ezetimibe reduced MACE by 17% in CKD)

Caveat:

• PLANET I study: at high doses (rosuvastatin 40 mg), rosuvastatin increased proteinuria more than atorvastatin - this is why 5-10 mg, not 40 mg, is the right dose here
• At low-moderate doses (5-10 mg): renal benefit outweighs any risk

2. Ezetimibe - Renoprotective when combined with statin ✅

Evidence:

• SHARP trial (9,270 CKD patients): Simvastatin + Ezetimibe reduced major atherosclerotic events by 17% in CKD patients - landmark trial specifically in CKD
• IMPROVE-IT trial: ezetimibe added to statin further reduced cardiovascular events
• Ezetimibe does not affect eGFR directly - renal benefit comes from CV risk reduction

Pharmacokinetics in renal impairment:

• Ezetimibe is primarily metabolized in the intestine and liver - not renally excreted
• In severe renal disease (CrCl <30), AUC increases ~1.5x - manageable, no dose adjustment needed
• At creatinine 1.1 / eGFR 78: no dose adjustment required, full benefit maintained

3. Fenofibrate - Complex Renal Picture ⚠️ (Protective in the long term, but raises creatinine short-term)

The Creatinine Paradox:

Long-term Evidence - Actually Renoprotective:

• Fenofibrate delays progression to dialysis - RCT in advanced CKD showed fenofibrate reduced the need for dialysis (Yen et al., J Clin Endocrinol Metab 2021)
• Reduces albuminuria and proteinuria (strong evidence from FIELD and ACCORD trials)
• ACCORD-LIPID trial: fenofibrate + statin reduced albumin:creatinine ratio progression
• PPARα activation in the kidney reduces:
  • Renal inflammation
  • Glomerular hypertension
  • Tubulo-interstitial fibrosis
  • Oxidative stress

Applied to This Patient:

• Creatinine currently 1.1 - expect it to rise to ~1.2-1.25 after starting fenofibrate
• This is a tubular secretion effect, not nephrotoxicity - do not panic and stop the drug
• True renal function (eGFR by cystatin C) will remain stable or improve
• If creatinine rises >1.5 on fenofibrate → stop and reassess

4. Omega-3 Fatty Acids (EPA/DHA) - Renoprotective ✅

Evidence:

• Omega-3 reduces urinary albumin excretion in both diabetic and non-diabetic kidney disease
• Reduces glomerular hyperfiltration (relevant in pre-diabetic state)
• Anti-inflammatory: reduces TGF-β mediated renal fibrosis
• ASCEND trial: omega-3 reduced renal outcomes in diabetic patients
• No nephrotoxicity, no creatinine elevation, no dose adjustment needed in any stage of CKD

5. Vitamin E - Mildly Renoprotective ✅

• Reduces oxidative stress in tubular cells and mesangium
• In NAFLD with renal impairment, reduces lipid peroxidation products that damage tubular epithelium
• No nephrotoxicity at 400 IU/day

6. Levothyroxine (already on) - Renoprotective ✅

• Thyroid hormones directly regulate renal hemodynamics, GFR, tubular sodium reabsorption, and renal blood flow
• His creatinine rose to 1.8 because of hypothyroidism (TSH 110 causing rhabdomyolysis + reduced renal perfusion)
• Now with TSH 0.68 and euthyroid state, renal perfusion and GFR are restored
• Maintaining euthyroid state IS the primary renal protective strategy in this patient

Summary Table - Renal Profile of Each Drug

Specific Monitoring for This Patient's Kidneys

The Bigger Picture for This Patient's Kidneys

1. Uncontrolled dyslipidemia - lipid deposition in glomeruli accelerates nephron loss → being treated ✅
2. Pre-diabetes progression to T2DM - diabetic nephropathy is the leading cause of ESRD → monitor HbA1c, lifestyle intensification, consider Metformin if HbA1c reaches 5.7+
3. Another hypothyroid episode - TSH 110 nearly caused ESRD → never miss levothyroxine doses, regular TSH monitoring ✅

Part 1 - Are These Drugs Lifelong?

Rosuvastatin - Answer: For This Patient, Likely Lifelong

• His dyslipidemia is driven by both his thyroid condition (ongoing autoimmune destruction) AND metabolic syndrome components
• TC/HDL ratio of 7 puts him at high ASCVD lifetime risk at age 34
• Even with perfect lifestyle, Hashimoto's will continue to suppress LDL receptor activity to some degree
• However - if at his 12-month review his LDL is <100, TG <150, and he has achieved substantial lifestyle changes with weight loss, a dose reduction to 5 mg or reassessment is entirely reasonable

Ezetimibe - Answer: Not necessarily lifelong - reassess at 12 months

• If LDL falls below 70 mg/dL at 12 weeks on Rosuvastatin 5 mg + Ezetimibe → could trial stopping ezetimibe and see if LDL remains at target on statin alone
• If LDL holds at target without ezetimibe → can stop ezetimibe
• If LDL drifts up without ezetimibe → restart it
• Ezetimibe has no significant side effects and is very well-tolerated, so there is no strong reason to stop it if it is doing its job

Fenofibrate - Answer: Duration tied to TG control and NAFLD status

• If TG reaches <150 and NAFLD resolves (confirmed on ultrasound) AND lifestyle is excellent → can attempt stopping fenofibrate after 12-18 months
• TG tends to rebound when fibrates are stopped in patients with metabolic syndrome unless root causes (diet, weight, insulin resistance) are addressed
• If pre-diabetes progresses to T2DM → fenofibrate should continue long-term (strong evidence for TG reduction and renal protection in diabetics)
• If lifestyle reverses the metabolic syndrome (achievable at 34 with effort) → fenofibrate may become unnecessary

Part 2 - Does Rosuvastatin Cause Myopathy and Muscle Loss?

The Honest Answer: Yes, It Can - But the Risk is Low and Stratified

Does Rosuvastatin Cause Sarcopenia / True Muscle Loss?

• Myalgia = muscle pain - no structural loss, fully reversible
• Myopathy = muscle inflammation - reversible with stopping drug (weeks to months)
• Rhabdomyolysis = acute muscle breakdown - reversible with prompt treatment
• Long-term sarcopenia (actual muscle wasting) - NOT a well-established effect of statins at low-moderate doses

1. It is hydrophilic - does not penetrate muscle cells as readily as lipophilic statins (simvastatin, atorvastatin)
2. It does not depend on CYP3A4 - avoids pharmacokinetic accumulation
3. Achieves high LDL reduction at low doses - so you never need to push to high doses

Does Fenofibrate Cause Myopathy?

• Fibrate alone: mild myalgia in 1-3%
• Fenofibrate + Rosuvastatin: modest increase in myopathy risk (lower than gemfibrozil + statin)
• Per FDA label: "Fibrates may cause myopathy when given alone. The risk is increased with concomitant use with statins. Consider whether the benefit of using fibrates with Rosuvastatin/Ezetimibe outweighs the risk."

Does Ezetimibe Cause Myopathy?

Part 3 - How to Prevent Muscle Damage (Active Prevention Strategy)

Prevention Pillar 1 - Right Drug Choice (Already Done)

Prevention Pillar 2 - Vitamin D Supplementation (Already Prescribed - Critical)

• Vitamin D deficiency is an independent risk factor for statin-associated muscle symptoms (SAMS)
• His Vitamin D is 30 ng/mL - borderline. Target should be 40-60 ng/mL
• Vitamin D receptors are present in skeletal muscle - deficiency impairs muscle cell mitochondrial function
• Studies show correcting Vitamin D deficiency before starting statins significantly reduces myalgia rates

Prevention Pillar 3 - Coenzyme Q10 (CoQ10) - Nuanced Evidence

• CoQ10 is very safe at therapeutic doses (100-200 mg/day)
• Well tolerated (GI upset <1%)
• Some patients report subjective improvement in muscle symptoms
• No harm in supplementing

Prevention Pillar 4 - Exercise (Paradoxically Protective)

• Regular moderate-intensity aerobic exercise (150 min/week) actually reduces the incidence of SAMS in statin users in several observational studies
• Exercise improves mitochondrial density and CoQ10 stores in muscle independently
• However: intense acute exercise (marathon, heavy gym session) acutely raises CK - if done while on statin + fenofibrate, can trigger symptomatic myopathy
• Advice: Regular moderate exercise = protective. Extreme acute bouts = avoid, especially in first 3 months

Prevention Pillar 5 - Drug Interaction Vigilance

Prevention Pillar 6 - Avoid Precipitating Factors

• Major surgery or trauma - temporarily hold statin and fenofibrate perioperatively (discuss with surgeon)
• Severe infection or sepsis - hold statins temporarily
• Acute dehydration - increases CK concentration
• Hypothyroid relapse - if TSH rises again, myopathy risk climbs sharply → this is why thyroid monitoring is part of the muscle protection plan
• Alcohol excess - independently raises CK and worsens myopathy risk

Prevention Pillar 7 - What the Patient Must Do Themselves

1. Any muscle pain, tenderness, or weakness in the legs, arms, or back → stop statin + fenofibrate and call doctor
2. Dark brown or cola-coloured urine → emergency - rhabdomyolysis - go to hospital immediately
3. Flu-like symptoms with muscle aches → do not dismiss as a viral illness - CK check required
4. Do not restart either drug on his own after stopping - needs CK check first

Summary Table

One Key Practical Point

• 7-10% body weight loss → reduces TG by 20-30%, raises HDL, can normalize FBS
• Mediterranean diet + aerobic exercise → may allow fenofibrate to be stopped in 12-18 months
• Maintaining euthyroid state → removes the biggest driver of his dyslipidemia
• At each annual review → reassess whether doses can be reduced or drugs stopped based on targets met

Diet Strategy - Built Around 5 Conditions Simultaneously

The Mediterranean Diet - Core Framework

Every meal plate should look like this:

50% → Non-starchy vegetables (raw or cooked)
25% → Whole grains or legumes
25% → Lean protein (fish preferred, chicken, eggs, legumes)
    + Generous olive oil as cooking fat
    + Small amounts of nuts/seeds as snacks
    + Fruit as dessert
    + Fish 2-3 times per week

Part 1 - FOODS TO EAT FREELY (Every Day)

Vegetables - The Foundation

Fruits - Eat, But Choose Wisely

Fats - The Right Fats Are Medicine

Proteins - Lean and Plant-Forward

Grains - Whole, Always

Thyroid-Specific Foods (Hashimoto's Support)

Part 2 - THE BIG FOUR TO ELIMINATE (Most Important)

1. Sugar and Fructose - TG's Biggest Enemy

• Cold drinks / soft drinks / cola - a single 330ml can = 35g sugar = major TG spike
• Packaged fruit juices ("natural" or not)
• Sweets, mithai, halwa, gulab jamun, jalebi
• Sugar in tea/coffee (switch to no sugar)
• Energy drinks
• Flavoured yoghurt / flavoured milk
• Biscuits, cookies, cakes

2. Saturated and Trans Fats - LDL's Biggest Enemy

• Ghee in large amounts (small amounts in cooking - 1 tsp - is tolerable)
• Butter - switch to olive oil spread or none
• Dalda / vanaspati / hydrogenated vegetable oil - trans fat = worst lipid offender
• Palm oil based processed foods (most Indian namkeen, chips)
• Full-fat dairy - switch to low-fat milk, curd, paneer
• Red meat (mutton, beef, pork) - high saturated fat; limit to once a week maximum
• Fried foods - samosa, pakoda, puri, vada - eliminate entirely
• Processed meat - sausages, salami, ham

3. Refined Carbohydrates - TG + Pre-diabetes Driver

• White rice more than 1 small cup/meal
• White bread, toast
• Maida roti, naan, paratha
• Instant noodles (Maggi etc)
• Breakfast cereals (corn flakes, muesli with sugar)
• Packaged namkeen, farsan

4. Alcohol - Direct TG Elevator

• Complete abstinence is recommended given TG 242 + NAFLD
• Even "one drink" can raise TG by 20-50 mg/dL acutely
• Beer is particularly harmful (malted barley = high glycemic + alcohol combined)

Part 3 - SPECIAL FUNCTIONAL FOODS (Proven Cholesterol-Lowering)

Part 4 - LEVOTHYROXINE INTERACTION WITH FOOD

Part 5 - SAMPLE INDIAN MEAL PLAN (1 Day)

Part 6 - WHAT TO DRINK

Part 7 - EXERCISE AS DIETARY PARTNER

Summary - The 10 Most Impactful Changes

Short Answer

Part 1 - How Broccoli and Cabbage Lower Cholesterol

Mechanism 1 - Bile Acid Binding (Most Important)

• Cruciferous vegetables contain fiber and glucosinolates that bind bile acids in the intestine
• Bile acids are made from cholesterol in the liver
• When they are bound and excreted in stool instead of being reabsorbed, the liver must pull more LDL from the blood to make new bile acids
• Result: LDL receptors upregulate → LDL falls
• This is the same mechanism as cholestyramine (a prescription bile acid sequestrant) - just much milder

Mechanism 2 - Glucosinolates and Sulforaphane (Broccoli-Specific)

• Broccoli contains glucoraphanin, which converts to sulforaphane during chewing/digestion
• Sulforaphane activates the Nrf2 pathway → reduces hepatic cholesterol synthesis
• A 12-week RCT using high-glucosinolate broccoli (400g/week) showed a significant reduction in LDL-cholesterol compared to standard broccoli (Linus Pauling Institute data)
• Sulforaphane also reduces oxidized LDL - the most dangerous form that causes atherosclerotic plaques

Mechanism 3 - Fiber Content

Mechanism 4 - Phytosterols

Mechanism 5 - Anti-inflammatory (Relevant for Hashimoto's + Dyslipidemia)

• Sulforaphane, indole-3-carbinol, and Vitamin C in broccoli are potent anti-inflammatory compounds
• Chronic inflammation (as in Hashimoto's) independently promotes LDL oxidation and atherosclerosis
• Anti-inflammatory vegetables reduce this residual cardiovascular risk beyond just cholesterol numbers

Part 2 - The Hashimoto's / Hypothyroidism Concern (Goitrogens)

What Are Goitrogens?

• Goitrin - mildly interferes with thyroid hormone synthesis
• Thiocyanates - competes with iodine uptake by the thyroid gland

The Evidence - Much Less Scary Than Feared

The Cooking Difference - Critical for This Patient

One More Reassurance for This Patient

• He is on levothyroxine 100 mcg - his thyroid hormone is coming from the tablet, not his own gland
• Even if small amounts of thiocyanate were absorbed, they cannot compete meaningfully with an oral levothyroxine dose
• His TSH is 0.68 - well-controlled - cooked cruciferous vegetables will not shift this
• The only interaction to genuinely watch is timing - do not eat broccoli or cabbage immediately before taking levothyroxine (the general rule of eating 30-60 min after levothyroxine covers this automatically)

Practical Verdict for Prashanth

How Much and How Often

• Broccoli: 1 cup cooked, 3-5 times per week - ideal
• Cabbage: 1 cup cooked, 3-4 times per week - ideal
• Expected cholesterol effect: Modest independently (3-7% LDL reduction as part of overall dietary pattern), but their real value is as part of the total Mediterranean-style vegetable load which collectively gives 15-25% LDL reduction

The Bottom Line in One Sentence